---
title: "Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: References"
description: "Reference list for the formulary evidence report on Zeleciment rostudirsen (z-rostudirsen, DYNE-251) in Duchenne muscular dystrophy. 77 cited documents."
canonical: "https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: References

<a id="references"></a>

## 5 References

1. [Aartsma-Rus et al. (2009)](https://onlinelibrary.wiley.com/doi/10.1002/humu.20918)
2. [Ayyar Gupta et al. (2023)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0283669)
3. [Bever et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03700-6)
4. [Birnkrant et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5869704/)
5. [Birnkrant et al. (2018b)](https://stacks.cdc.gov/view/cdc/53174/cdc_53174_DS1.pdf)
6. [Birnkrant et al. (2018c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5902408/)
7. [Borecka et al. (2026)](https://link.springer.com/article/10.1186/s41687-026-01055-8)
8. [Broomfield et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8665435/)
9. [Broomfield et al. (2024a)](https://link.springer.com/article/10.1007/s41669-023-00450-x)
10. [Broomfield et al. (2024b)](https://link.springer.com/article/10.1007/s41669-024-00506-6)
11. [Burnette (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28107)
12. [Centers for Disease Control and Prevention (2025)](https://www.cdc.gov/muscular-dystrophy/research/summary.html)
13. [Crisafulli et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7275323/)
14. [Davis et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Davis_SOT_March_2026.pdf)
15. [de Feraudy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33159473/)
16. [De Waele et al. (2024)](https://www.dyne-tx.com/wp-content/uploads/De_Waele_DELIVER_WMS_2024.pdf)
17. [Desjardins et al. (2022a)](https://www.dyne-tx.com/wp-content/uploads/gkac641.pdf)
18. [Desjardins et al. (2022b)](https://www.dyne-tx.com/wp-content/uploads/2022_WMS_Poster_FINAL.pdf)
19. [Desjardins et al. (2023)](https://www.dyne-tx.com/wp-content/uploads/Desjardins_Et_al_MDA%202023_D2_Mdx_Mouse.pdf)
20. [Desjardins et al. (2025)](https://www.dyne-tx.com/wp-content/uploads/Desjardins_2025_WMS_DMD%20CNS%20Poster.pdf)
21. [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)
22. [DMD Hub](https://dmdhub.org/trials/dyne-therapeutics-dyne-251/)
23. [Duvuru et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1119/)
24. [Dyne Therapeutics (2022)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-receives-fda-fast-track-designation-dyne-251/)
25. [Dyne Therapeutics (2023)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-receives-fda-orphan-drug-and-rare-pediatric/)
26. [Dyne Therapeutics Biologics License Application acceptance announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-us-fda-acceptance-biologics-license)
27. [Dyne Therapeutics Biologics License Application submission announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-submission-biologics-license)
28. [Dyne Therapeutics breakthrough therapy designation announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-fda-breakthrough-therapy-0)
29. [Dyne Therapeutics cardiopulmonary results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-positive-cardiopulmonary-results/)
30. [Dyne Therapeutics clinical trials page](https://www.dyne-tx.com/clinical-trials/)
31. [Dyne Therapeutics DELIVER long-term clinical data announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-long-term-clinical-data-phase-12)
32. [Dyne Therapeutics DELIVER topline results announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-topline-results-phase-12)
33. [Dyne Therapeutics first quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-first-quarter-2026-financial-results)
34. [Dyne Therapeutics FORZETTO initiation announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-initiation-phase-3-forzetto-trial-z)
35. [Dyne Therapeutics initial DELIVER clinical data announcement (2024)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-initial-clinical-data)
36. [Dyne Therapeutics investor presentation (2026)](https://investors.dyne-tx.com/static-files/9a27ae49-fa3f-4bd6-8711-029549461129)
37. [Dyne Therapeutics new DELIVER clinical data announcement (2024)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-clinical-data-phase-12-deliver)
38. [Dyne Therapeutics pipeline page](https://www.dyne-tx.com/pipeline/)
39. [Dyne Therapeutics second quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-second-quarter-2026-financial-results)
40. [Dyne Therapeutics third quarter 2025 results announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-third-quarter-2025-financial-results)
41. [Dyne Therapeutics third quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-third-quarter-2026-financial-results)
42. [EU Clinical Trials Register 2021-005478-24](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005478-24/BE)
43. [Fang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11867578/)
44. [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy)
45. [FDA (2025)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal)
46. [FDA EXONDYS 51 prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206488s035lbl.pdf)
47. [Flanigan et al. (2024)](https://www.mdaconference.org/abstract-library/initial-data-from-the-deliver-trial-of-dyne-251-in-males-with-dmd-mutations-amenable-to-exon-51-skipping/)
48. [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf)
49. [Fratter et al. (2020)](https://www.nature.com/articles/s41431-020-0643-7)
50. [Furlong et al. (2024)](https://link.springer.com/article/10.1186/s40900-023-00535-1)
51. [Guglieri et al. (2025a)](https://img1.wsimg.com/blobby/go/c41fb68b-e89f-48ad-ac1b-afa320649a21/downloads/5c451111-82c2-484e-91ce-747526149a4b/Final%20Corticosteroids%20Guidance.pdf?ver=1777992903816)
52. [Guglieri et al. (2025b)](https://www.nmd-journal.com/article/S0960-8966%2825%2900359-1/fulltext)
53. [Guglieri et al. (2025c)](https://www.dyne-tx.com/wp-content/uploads/Guglieri_2025_WMS_DELIVER%20Poster.pdf)
54. [Health Resources and Services Administration](https://newbornscreening.hrsa.gov/conditions/duchenne-muscular-dystrophy)
55. [Hoffman and Clemens (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8251539/)
56. [ICER (2019)](https://icer.org/news-insights/press-releases/dmd_evidence_report/)
57. [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)
58. [Landfeldt et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859858/)
59. [Landfeldt et al. (2017)](https://link.springer.com/article/10.1007/s40273-016-0461-5)
60. [Landfeldt et al. (2026)](https://link.springer.com/article/10.1007/s40273-026-01610-7)
61. [Laverty et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Laverty_2026_MDA%20_DELIVER_LTE_Poster.pdf)
62. [Leckie et al. (2024)](https://doi.org/10.3390/genes15111489)
63. [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)
64. [Muntoni et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36725339/)
65. [Naylor et al. (2023)](https://www.dyne-tx.com/wp-content/uploads/Naylor_Et_al_MDA_2023_DELIVER_TiP.pdf)
66. [Naylor et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Naylor_2026_ICNMD_FORZETTO.pdf)
67. [Okada et al. (2026)](https://www.nature.com/articles/s41598-025-32735-y)
68. [Ong et al. (2018)](https://stacks.cdc.gov/view/cdc/61439)
69. [Parent Project Muscular Dystrophy caring for Duchenne page](https://www.parentprojectmd.org/care/for-healthcare-providers/caring-for-duchenne/)
70. [Parent Project Muscular Dystrophy genetic testing page](https://www.parentprojectmd.org/about-duchenne/genetic-causes/genetic-testing/)
71. [Phan et al. (2025)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2025_MDA_DELIVER_Poster.pdf)
72. [Scavina et al. (2026)](https://link.springer.com/article/10.1007/s41669-025-00612-z)
73. [Servais et al. (2024)](https://www.nature.com/articles/s41598-024-80177-9)
74. [Shieh et al. (2025)](https://www.neurology.org/doi/abs/10.1212/WNL.0000000000211198)
75. [University of California San Diego (2026)](https://clinicaltrials.ucsd.edu/trial/NCT05524883)
76. [Yip et al. (2026)](https://jheor.org/article/158537-systematic-literature-reviews-of-health-state-utility-values-costs-and-healthcare-resource-use-in-duchenne-muscular-dystrophy)
77. [Zygmunt et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28255)

## Related pages
- [Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Terms and abbreviations](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations.md)
- [Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Product information and disease description](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Clinical evidence](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Economic information and modeling report](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: prevalence by geography](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses.md)
